News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stock Titan Balance sheet
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Bioatla Inc (BCAB) has an earnings forecast score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. Analysts have a consensus price target of USD 10.00 and a "Strong Buy" rating for the stock. The company's previous quarter's EPS was USD -8.18, …
BioAtla, Inc. (BCAB) is scheduled to release its Q2'26 earnings on August 6th. Analysts estimate revenue to be $0 with an earnings per share (EPS) of ($8.50). This report provides a quick overview of estimated vs. reported EPS for previous quarters.
BioAtla, Inc. (BCAB) is scheduled to release its Q2'26 earnings on August 6, 2026, at 8:00 AM ET (12:00 PM UTC). The company's revenue estimate for the quarter is $0 USD, with an anticipated EPS (earnings per share) of ($8.50) USD.
This article details the shareholder structure of Bioatla Inc (BCAB), identifying its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings for top firms. The data focuses on …
This article provides a valuation analysis of Bioatla Inc (BCAB), detailing its current valuation score and P/E ratio. It notes that the company ranks highly within the Biotechnology & Medical Research industry for its valuation. However, key valuation metrics like P/B, P/S, and P/CF …
This article provides historical dividend and stock split information for Bioatla Inc (BCAB). It notes that no dividends have been distributed in the past 5 years and details a future merger stock split event scheduled for March 31, 2026, with a 50:1 ratio. The …
BioAtla, Inc. (NASDAQ: BCAB) revenue breakdown shows that the United States was the greatest contributor to its revenue. Last year, the U.S. accounted for $2.00 million USD, a decrease from $11.00 million USD the previous year. This data highlights the company's regional financial performance.
This article provides a detailed cash flow statement for Bioatla Inc (BCAB), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as net income, changes in working capital, capital expenditures, and debt issuance/repayment. The content also includes …
Bioatla Inc (BCAB) has an institutional shareholding score of 3.00, ranking 192 out of 386 in its industry. The institutional shareholding proportion is 19.70%, a quarter-over-quarter decrease of 68.85%. James Simons is the largest institutional shareholder with 0.62% of outstanding shares.
Bioatla Inc. (BCAB) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancer, with a valuation considered fairly valued. Despite an average stock market performance over the last month, the company shows strong fundamentals and high growth potential, although its …
BioAtla, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected two Class III directors, ratified Ernst & Young LLP as their independent auditor, and approved executive compensation on an advisory basis. The meeting, which had 55% representation of outstanding shares, addressed routine …
Search by ticker symbol or company name and select a result to open its chart.